Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing

– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for verekitug into third indication, strengthening pipeline across severe respiratory diseases including chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and COPD – – Program updates also include completion of enrollment in Phase 2 clinical trial in severe asthma; top-line data now expected in first quarter of 2026 – WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an in

– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to tezepelumab – – Supports potentially differentiated profile of verekitug across a broad range of inflammatory diseases, including severe asthma, chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP) – WALTHAM, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the presentation of translationa

WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced an upcoming presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, UK, on Sunday, June 15, 2025. The presentation features translational pharmacology modeling data that supports Thymic Stromal Lymphopoietin (TSLP) receptor targeting with verekitug as a mechanism for greater potency when compared to treatment approaches that target the TSLP ligand. Presentation details: Presentation Title: In silico system pharmac

WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025, at 9:20 a.m. ET. A live webcast of the fireside chat will be available under the "Events" tab on the "Investors" page of the Company's website on the day of the event. A replay of the webcast will be posted on the Company's website following the presentation. About Upst

WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr

– Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – – Top-line data from Phase 2 clinical trial of verekitug in patients with severe asthma now expected in the first half of 2026 – – First patient in Phase 2 clinical trial of verekitug in patients with chronic obstructive pulmonary disease to be dosed in mid-2025 – WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the first quarter ended Mar

– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 – – Completed upsized IPO with gross proceeds of approximately $293 million, extending runway through 2027 – WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a summary of recent business highlights. Upstream is developing verekitug, the only monoclonal

WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Upstream Bio's CEO, will present at the following upcoming March investor conferences: TD Cowen 45th Annual Health Care Conference, Boston MATuesday, March 4, 2025, 11:50 a.m. – 12:20 p.m. ET Leerink Partners Global Biopharma Conference 2025, Miami FLWednesday, March 12, 2025, 1:40 p.m. – 2:10 p.m. ET A live webcast of the presentation will be available under the "Events" tab on the "Investors" page of the Company's website on the day of

Upstream's 2025 Automotive & Smart Mobility Cybersecurity Report reveals that 60% of cyber incidents could affect thousands to millions of connected vehicles, with massive-scale attacks more than tripling; the report emphasizes that current regulatory requirements are insufficient to address expanding cyber risks. ANN ARBOR, Mich., Feb. 11, 2025 /PRNewswire/ -- Upstream Security, the leading provider of cloud-based cybersecurity and data management platform purpose-built for automotive, smart mobility, and IoT ecosystem, today released the 2025 Automotive & Smart Mobility Cybersecurity Report. The annual report, returning for its seventh year, highlights that despite the increased regulatory

Piper Sandler initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $75.00

JP Morgan initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $38.00

William Blair initiated coverage of Upstream Bio with a rating of Outperform

TD Cowen initiated coverage of Upstream Bio with a rating of Buy

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

8-K - Upstream Bio, Inc. (0002022626) (Filer)

10-Q - Upstream Bio, Inc. (0002022626) (Filer)

8-K - Upstream Bio, Inc. (0002022626) (Filer)

DEFA14A - Upstream Bio, Inc. (0002022626) (Filer)

DEF 14A - Upstream Bio, Inc. (0002022626) (Filer)

S-8 - Upstream Bio, Inc. (0002022626) (Filer)

10-K - Upstream Bio, Inc. (0002022626) (Filer)

8-K - Upstream Bio, Inc. (0002022626) (Filer)

SCHEDULE 13G - Upstream Bio, Inc. (0002022626) (Subject)

SCHEDULE 13G - Upstream Bio, Inc. (0002022626) (Subject)

WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr

WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company has appointed Allison Ambrose, J.D. as General Counsel. Ms. Ambrose is a senior legal leader with more than 15 years of experience providing counsel on a wide range of matters including corporate governance, securities law and compliance, and capital markets and corporate development transactions. Ms. Ambrose will oversee all aspects of Upstream's legal function and join the Company's executive leadership team. "I am thrilled to welcome Allison to

SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

SC 13D - Upstream Bio, Inc. (0002022626) (Subject)

SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

SC 13D - Upstream Bio, Inc. (0002022626) (Subject)